Alex Hillenbrand

A population-based analysis suggests age and sex specific eGFR percentiles and a web-based calculator can identify CKD risk before diagnostic thresholds.

New sequence analysis suggests racial and ethnic disparities in KRT are pronounced in younger adults, affecting mortality, transplantation, and dialysis modality use.

The Mortality Estimation in Renal Disease (MERD) score may help identify transplant candidates at highest risk of waitlist mortality.

A retrospective analysis does not link gentamicin with decreased risks of urinary tract infections after kidney transplantation.

Global analysis links elevated BMI and low physical activity to rising hypertension-related chronic kidney disease burden, with deaths projected to increase through 2050.

The FDA has extended its review of the sNDA, delaying the previous January 13, 2026, PDUFA date, to April 13, 2026.

A new national database study suggests malnutrition reverses the obesity survival benefit in hospitalized ESKD patients undergoing dialysis

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

A prospective study reports an association between diabetes mellitus and anuria with high post-void residual post-transplantation.

According to new research, investigators project a rising chronic kidney disease burden in young adults and a declining incidence in children by 2050.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression.

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability.

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN.

Retrospective data suggest serum creatinine trajectories might predict 28-day mortality in acute kidney injury on chronic kidney disease.

A cross-sectional study in CKD suggests patients undergoing hemodialysis have increased social frailty and depression compared to transplant recipients.

A qualitative descriptive study of pediatric kidney transplant recipients and caregivers highlights a need for standardized educational materials and treatment information.

New research in patients with end-stage kidney disease suggests an association between neighborhood advantage and access to transplants and waitlists.

In December 2025, intervention strategies, dialysis modalities, and kidney transplantation data provided insight to improve renal care for clinicians.

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options

FDA clears first human umbilical cord–derived sheet device, Theracor, for wound Care

The FDA grants breakthrough therapy designation for ulizacaltamine for the treatment of essential tremor.

IgA nephropathy advanced in 2025 with FDA approvals, positive phase 3 trials, and growing disease-modifying therapies

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).

A multi-state cross-sectional analysis linked chronic kidney disease with increased COVID-19 hospitalizations, indicating more severe disease outcomes

A cross-sectional study compares renal transplantation with dialysis, highlighting an improved sleep quality in end-stage renal disease.